The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients.

Conclusion. Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB. PMID: 26843983 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26843983?dopt=Abstract

Source: Anemia - February 5, 2016 Category: Hematology Tags: Anemia Source Type: research